Practical issues involved with the use of bortezomib

Published: June 8, 2009
Abstract Views: 146
PDF: 148
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The use of proteasome inhibition as a therapeutic target against human cancers represents an exciting new target either alone, or in combination with other agents. The use of single agent bortezomib in relapsed myeloma resulted in a 43% response rate, improved time to progression, and superior overall survival when compared with high dose dexamethasone in the randomized phase III APEX trial. This survival benefit continues to hold despite the cross-over use of bortezomib for patients initially randomized to receive dexamethasone, further solidifying the use of bortezomib as a standard approach for the management of relapsed myeloma.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Lonial, S. (2009). Practical issues involved with the use of bortezomib. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.408